Leaders in Partnering, M&A Deals and Strategic Alliances
What We Do
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 29 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts from innovators to large pharma makes us uniquely placed to support business in all aspects of deal making and strategic planning.
PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.
More about us
Our Services
M&A
Licensing
Fundraising
- M&A (divestments, mergers, acquisitions, and strategic transactions)
- Licensing (in and out licensing)
- Fundraising
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuation and Positioning (licensing, M&A, fundraising, and expert testimonies)
Our Latest Video
In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm.
Recipharm is a leading Swedish CDMO, founded in 1995, which has expanded to over 30 sites across 10 countries which are mainly in Europe, but also in Israel, India, and North America. The company’s successful inorganic growth has been largely through the build and buy model of its founders, according to Marc.
They discuss the company’s current situation and how Marc plans to take it forward, including:
- The takeover of Recipharm by EQT, a global investment organisation with a “passion for future-proofing companies”
- Focus on operational excellence, meeting the needs unmet by the competition, emerging technologies, and innovation
- Opportunities in the areas of small molecules, biologics, and North America
- Recipharm’s and EQT’s “priority 1” – customer focus
- Affordable and safe drugs
- How Recipharm are operating during the COVID-19 pandemic
- What Marc sees as his biggest challenges, both now and in the future
PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH
Oxford, UK, 03 March 2021 PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH. ERA Consulting is a leading strategic...
For the Latest Industry Information
Our Track Record
We conducted a detailed assessment of the market opportunities, technology risks and developments, launch and marketing costs via scenarios of “go-it-alone”, “outright sale”, “out-licensing for royalties” as well as “out-licensing with co-promotion”. The value generated was modelled and the scenarios were prioritised. Partnering and deal strategies were developed for the selected optimal strategy and incorporated into a business plan.
PharmaVentures developed a customised search strategy based on the specific requirements of the client, which involved a systemic country by country identification of candidates with the correct therapeutic indications, combined with their commercial potential and availability for the territories of interest.
PharmaVentures conducted a compound valuation (bottom-up and benchmarking using PharmaDeals Agreements® data) providing the basis for future negotiations. We also carried out a thorough company screening and evaluation assessment to identify and prioritise potential licensees. Following the screening, within the space of a month our transaction team approached all the target companies with a carefully constructed value proposition using a non-confidential information package.
PharmaVentures’ Industry Insight: We predict that licensing and partnering activity will remain steady in 2020
As we all know deal making is the life and blood of the biopharma industry and today this activity is truer than ever. In my experience of thirty years in deal making, companies who were most active...
Our Clients
What Our Clients Say
“I feel I made an excellent choice in PharmaVentures to serve as my exclusive advisors for the sale of the Company. They have a comprehensive understanding of our business and helped me identify the ideal partner that shared our strategic vision…I truly value the professional advice and the expert guidance made through every step of the process which enabled us to close the transaction to the satisfaction of all stakeholders.”